Chloroquine-Resistant Malaria: Pharmacotherapy Management

Background and Resistance Epidemiology

Diagnostic Algorithm

I. Uncomplicated Chloroquine-Resistant P. falciparum (Oral Therapy)

First-Line: Artemisinin-Based Combination Therapies (ACTs)

1. Artemether-Lumefantrine (Coartem) - FDA-approved first choice in the US

2. Atovaquone-Proguanil (Malarone)

3. Quinine Sulfate + Partner Drug

4. Mefloquine (Monotherapy or Alternative)

• Dose: 750 mg orally, then 500 mg 6-12 h later (total 1250 mg in adults); 25 mg/kg split over 24 h in children
• Effective for chloroquine-resistant strains but not recommended for infections acquired in Southeast Asia due to high mefloquine resistance
• Neuropsychiatric adverse effects (anxiety, vivid dreams, psychosis, seizures) limit use; contraindicated with concurrent quinine

II. Uncomplicated Chloroquine-Resistant P. vivax (CRPV)

1. Atovaquone-proguanil (as above dosing)
2. Artemether-lumefantrine (as above dosing)
3. Mefloquine (as above dosing; use if no other option in children <8 yr)

For patients acquiring P. vivax outside Papua New Guinea or Indonesia: start with chloroquine; if the patient does not respond, switch to a CRPV regimen and notify the CDC. - Red Book 2021, p. 1400

III. Severe/Complicated Malaria (Parenteral Therapy)

Preferred: Intravenous Artesunate

Alternative if Artesunate Unavailable: IV Quinidine Gluconate (historical)

IV. Other ACT Regimens (WHO-endorsed, widely used outside US)

• Goodman & Gilman's, p. 1321

V. Special Populations

Pregnancy

• Atovaquone-proguanil: not generally recommended in pregnancy (limited safety data)
• Doxycycline/tetracycline: avoid in pregnancy unless no other option
• Do NOT use primaquine or tafenoquine (risk of hemolysis in G6PD-unknown fetus)
• Maintain chloroquine prophylaxis through pregnancy for P. vivax/ovale; treat hypnozoites postpartum

Children <8 years

• Atovaquone-proguanil (>5 kg): safe, preferred
• Artemether-lumefantrine (>5 kg): safe, preferred
• Mefloquine: if no other option available
• Doxycycline/tetracycline: avoid except in emergency
• Clindamycin replaces doxycycline as quinine partner in this age group

G6PD Deficiency

• Avoid primaquine and tafenoquine in G6PD-deficient patients (risk of hemolytic anemia)
• If radical cure is necessary in mild G6PD deficiency: primaquine 45 mg once weekly x 8 weeks with expert consultation

VI. Chemoprophylaxis in Chloroquine-Resistant Areas

VII. Resistance Mechanisms and Emerging Threats

• Ganaplacide (KAF156) - imidazolopiperazine; active on asexual forms and gametocytes of both P. falciparum and P. vivax (Phase II with solid dispersible lumefantrine)
• Cipargamin (KAE609) - spiroindolone; blood schizonticide (field trials)
• Ferroquine + artefenomel - retains activity against chloroquine-resistant AND piperaquine-resistant strains
• Monoclonal antibodies targeting PfCSP (Phase I) - Goodman & Gilman's, p. 1322

Quick Reference Summary Table

• Goodman & Gilman's The Pharmacological Basis of Therapeutics (Tables 66-2 and 66-3), pp. 1321-1324
• Katzung's Basic and Clinical Pharmacology, 16th Ed., pp. 1438-1444
• Lippincott Illustrated Reviews: Pharmacology, pp. 1176-1178
• Red Book 2021 (AAP), pp. 1399-1400
• CDC Malaria Hotline for IV artesunate access: 770-488-7100

Lower UTI due to Pseudomonas aeruginosa - Complete Pharmacotherapy Guide

Why Pseudomonas UTI is Clinically Significant

I. Drugs Used for Pseudomonas Lower UTI

A. Fluoroquinolones (Oral - First-line for uncomplicated lower UTI)

B. Antipseudomonal β-Lactams (IV - For complicated/hospitalized cases)

C. Aminoglycosides

D. Polymyxins (Reserve agents - MDR/XDR strains)

E. Novel β-Lactam/β-Lactamase Inhibitor Combinations (MDR strains)

II. Mechanism of Action of Each Drug Class

1. Fluoroquinolones (Ciprofloxacin, Levofloxacin)

• Target: Bacterial topoisomerase II (DNA gyrase, encoded by gyrA/gyrB) and topoisomerase IV (encoded by parC/parE)
• Action: Bind to and stabilize the DNA-enzyme complex, preventing re-ligation of DNA strands after the enzyme cuts them for replication and transcription - this leads to double-strand DNA breaks
• Net effect: Bactericidal - prevents DNA replication, transcription, repair and recombination
• Pseudomonas is susceptible primarily via DNA gyrase inhibition (GyrA subunit is the primary target)

2. β-Lactams (Penicillins, Cephalosporins, Carbapenems, Monobactams)

• Target: Penicillin-binding proteins (PBPs) - specifically transpeptidase enzymes in the bacterial cell membrane
• Action: Structurally mimic the terminal D-Ala-D-Ala portion of peptidoglycan precursors; covalently bind and irreversibly inhibit PBPs, blocking transpeptidation - the final cross-linking step of peptidoglycan cell wall synthesis
• Loss of structural integrity → osmotic lysis → bactericidal
• β-lactamase inhibitors (tazobactam, avibactam, vaborbactam, relebactam) bind and irreversibly inactivate β-lactamase enzymes, protecting the β-lactam partner from hydrolysis
• Cefiderocol additionally acts as a siderophore - chelates free iron and uses bacterial iron-uptake channels to achieve high periplasmic concentrations, overcoming efflux-pump and porin-loss resistance

3. Aminoglycosides (Tobramycin, Gentamicin, Amikacin)

• Target: 30S ribosomal subunit (16S rRNA)
• Action (3-step process):
  1. Ionic binding to the negatively charged outer membrane, displacing Ca²+ and Mg²+ → increases membrane permeability
  2. Energy-dependent phase I (EDP-I): Small amounts enter and bind to the 30S subunit → misreading of mRNA codons → production of abnormal proteins → inserted into cell membrane → increased permeability
  3. Energy-dependent phase II (EDP-II): Massive drug influx → complete inhibition of protein synthesis
• Net effect: Concentration-dependent bactericidal killing
• Resistance via: (a) efflux pumps, (b) decreased uptake, (c) aminoglycoside-modifying enzymes (AMEs) encoded on plasmids - amikacin and plazomicin are least affected by AMEs

4. Polymyxins (Colistin/Polymyxin E, Polymyxin B)

• Target: Gram-negative outer membrane (lipopolysaccharide - LPS)
• Action: Cationic cyclic peptides that bind to the negatively charged phosphate groups of lipid A (LPS component); this electrostatic interaction displaces Ca²+ and Mg²+ that stabilize the outer membrane, disrupting and permeabilizing both the outer membrane and cytoplasmic membrane
• Result: Cell contents leak out → rapid bactericidal killing (detergent-like effect)
• Resistance can emerge via mcr-1 (plasmid-mediated phosphoethanolamine transferase) that reduces negative charge on the cell surface, reducing polymyxin binding - Harrison's Principles of Internal Medicine 22E, p. 1229

III. Adverse Effects

1. Fluoroquinolones

2. Antipseudomonal β-Lactams (Piperacillin-tazobactam, Ceftazidime, Cefepime, Carbapenems)

3. Aminoglycosides

4. Polymyxins (Colistin, Polymyxin B)

IV. Patient Instructions to Prevent Future Pseudomonas UTI

Hygiene and Behavioral Measures

1. Wipe front to back after bowel movements (in women) - prevents fecal organisms, including Pseudomonas, from reaching the urethra
2. Void before and after sexual intercourse - flushes out any organisms introduced during activity
3. Do not delay urination - avoid "holding" urine for prolonged periods; urinate every 3-4 hours
4. Adequate hydration - drink 6-8 glasses (1.5-2 L) of water daily to dilute urine and flush the urinary tract
5. Avoid harsh soaps, douches, or bubble baths in the genital area - these disrupt natural flora and can introduce pathogens
6. Wear breathable, cotton underwear and avoid tight-fitting clothing that traps moisture

Catheter-Specific Instructions (if applicable)

1. Limit catheter use - use urinary catheters only when medically necessary; remove as early as possible
2. Maintain closed drainage system - never disconnect the catheter from the drainage bag unnecessarily
3. Keep drainage bag below bladder level at all times to prevent backflow
4. Daily catheter hygiene - clean the urethral meatus and catheter junction with soap and water daily
5. Change catheters regularly per medical advice - do not reuse disposable catheters

Medication and Compliance

1. Complete the full antibiotic course - never stop antibiotics early even if symptoms resolve; incomplete treatment promotes resistance
2. Do not self-medicate - never use leftover antibiotics for UTI symptoms; Pseudomonas requires sensitivity-guided therapy
3. Disclose all medications - inform your doctor of any immunosuppressants or corticosteroids, as these increase susceptibility

Risk Factor Modification

1. Manage underlying conditions - control diabetes optimally (high blood glucose promotes bacterial growth in urine)
2. Treat urinary obstruction - bladder stones, enlarged prostate (BPH), or strictures must be addressed, as these predispose to recurrent infections
3. Probiotic consideration - Lactobacillus-based probiotics may help restore normal urinary/vaginal flora (discuss with physician)
4. Avoid antibiotic overuse - prior antibiotic exposure is a key risk factor for Pseudomonas UTI; use antibiotics only when prescribed

When to Seek Immediate Care

• Fever >38°C, rigors, flank pain, or back pain (suggests upper tract spread/pyelonephritis)
• Gross hematuria (blood in urine)
• Worsening symptoms despite antibiotics
• Persistent symptoms >48 hours after starting treatment

Quick Summary Table

• Lippincott Illustrated Reviews: Pharmacology, pp. 993-997
• Goodman & Gilman's The Pharmacological Basis of Therapeutics, pp. 1177-1178
• Harrison's Principles of Internal Medicine 22E, pp. 1228-1229
• Bailey and Love's Short Practice of Surgery 28th Ed.